Key facts
- This page summarizes Fred Aslan's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
- 7 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 12 Dec 2025, 19:19.
Fred Aslan - 12 Dec 2025 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- ARTV
- Reported as of
- 12 Dec 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Dec 2025, 19:19:00 UTC
- Prior SEC filing
- 17 Nov 2025
- Next SEC filing
- 15 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Cronauer, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Fred Aslan filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 12 Dec 2025.
Change
- Previous filing in this sequence was filed on 17 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001909362
Primary reporting owner
Aslan Fred
- Relationship
- President and CEO, Director
- Address
- C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO
- Signature
- /s/ Andrew Cronauer, Attorney-in-Fact
- Signature date
- 12 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARTV
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +869,136
- Change %
- +253%
- Price
- $0.000000
- Shares after
- 1,213,135
- Date
- 12 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARTV
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -100,577
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,577
- Exercise price
- $5.01
- Footnotes
- F2, F3
ARTV
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -51,463
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 51,463
- Exercise price
- $5.01
- Footnotes
- F2, F3
ARTV
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -257,319
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 257,319
- Exercise price
- $5.01
- Footnotes
- F2, F4
ARTV
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -26,450
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,450
- Exercise price
- $5.18
- Footnotes
- F2, F5
ARTV
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -113,999
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 113,999
- Exercise price
- $13.47
- Footnotes
- F2, F6
ARTV
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -319,331
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 319,331
- Exercise price
- $12.00
- Footnotes
- F2, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").
Footnote F2
On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
Footnote F3
25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
Footnote F4
25% of the shares vest on January 1, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
Footnote F5
Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.
Footnote F6
25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.